164 related articles for article (PubMed ID: 90760)
1. Hypertriglyceridaemia associated with an abnormal triglyceride-rich lipoprotein carrying excess apolipoprotein C-III-2.
Stocks J; Holdsworth G; Galton D
Lancet; 1979 Sep; 2(8144):667-71. PubMed ID: 90760
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of apolipoprotein B-100 and of triglyceride-rich lipoprotein particles in the absence of functional lipoprotein lipase.
Pacy PJ; Mitropoulos KA; Venkatesan S; Watts GF; Reeves BE; Halliday D
Atherosclerosis; 1993 Nov; 103(2):231-43. PubMed ID: 8292098
[TBL] [Abstract][Full Text] [Related]
3. An abnormal triglyceride-rich lipoprotein containing excess sialylated apolipoprotein C-III.
Holdsworth G; Stocks J; Dodson P; Galton DJ
J Clin Invest; 1982 Apr; 69(4):932-9. PubMed ID: 7076853
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
Ginsberg HN; Le NA; Goldberg IJ; Gibson JC; Rubinstein A; Wang-Iverson P; Norum R; Brown WV
J Clin Invest; 1986 Nov; 78(5):1287-95. PubMed ID: 3095375
[TBL] [Abstract][Full Text] [Related]
5. Deficiency of hepatic lipase activity in post-heparin plasma in familial hyper-alpha-triglyceridemia.
Carlson LA; Holmquist L; Nilsson-Ehle P
Acta Med Scand; 1986; 219(5):435-47. PubMed ID: 3739751
[TBL] [Abstract][Full Text] [Related]
6. Distribution of apolipoprotein(a) in the plasma from patients with lipoprotein lipase deficiency and with type III hyperlipoproteinemia. No evidence for a triglyceride-rich precursor of lipoprotein(a).
Sandholzer C; Feussner G; Brunzell J; Utermann G
J Clin Invest; 1992 Nov; 90(5):1958-65. PubMed ID: 1430218
[TBL] [Abstract][Full Text] [Related]
7. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
[TBL] [Abstract][Full Text] [Related]
8. Severe hypertriglyceridaemia associated with altered apolipoprotein C and E composition of the triglyceride-rich lipoproteins.
Stalenhoef AF; Demacker PN; Lutterman JA; Van't Laar A
Neth J Med; 1981; 24(4):145-51. PubMed ID: 7279085
[No Abstract] [Full Text] [Related]
9. Adipose tissue lipoprotein lipase activity in type III hyperlipoproteinemia.
Goldberg AP; Applebaum-Bowden DM; Hazzard WR
Metabolism; 1979 Nov; 28(11):1122-6. PubMed ID: 226832
[TBL] [Abstract][Full Text] [Related]
10. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
Saku K; Sasaki J; Arakawa K
Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
[TBL] [Abstract][Full Text] [Related]
11. Is decreased activity of C-II activated lipoprotein lipase in type III hyperlipoproteinemia (broad-beta-disease) a cause or an effect of increased apolipoprotein E levels?
Ganesan D; Bass HB; McConathy WJ; Alaupovic P
Metabolism; 1976 Nov; 25(11):1189-95. PubMed ID: 185483
[TBL] [Abstract][Full Text] [Related]
12. Recent progress in the development of radioimmunoassays for human serum lipoproteins.
Karlin JB; Juhn DJ; Goldberg R; Rubenstein AH
Ann Clin Lab Sci; 1978; 8(2):142-54. PubMed ID: 205163
[TBL] [Abstract][Full Text] [Related]
13. The role of high density lipoprotein apolipoprotein CII in triglyceride metabolism.
Kashyap ML; Srivastava LS; Hynd BA; Perisutti G; Brady DW; Gartside P; Glueck CJ
Lipids; 1978 Dec; 13(12):933-42. PubMed ID: 220489
[No Abstract] [Full Text] [Related]
14. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.
Nikkilä EA; Ylikahri R; Huttunen JK
Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):58-63. PubMed ID: 190608
[TBL] [Abstract][Full Text] [Related]
15. Effect of heparin-induced lipolysis on the distribution of apolipoprotein e among lipoprotein subclasses. Studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase.
Rubinstein A; Gibson JC; Paterniti JR; Kakis G; Little A; Ginsberg HN; Brown WV
J Clin Invest; 1985 Feb; 75(2):710-21. PubMed ID: 3973025
[TBL] [Abstract][Full Text] [Related]
16. Studies on the mechanism of hypertriglyceridemia in Tangier disease. Determination of plasma lipolytic activities, k1 values and apolipoprotein composition of the major lipoprotein density classes.
Wang CS; Alaupovic P; Gregg RE; Brewer HB
Biochim Biophys Acta; 1987 Jul; 920(1):9-19. PubMed ID: 3109493
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiology of lipoprotein transport.
Brunzell JD; Chait A; Bierman EL
Metabolism; 1978 Sep; 27(9):1109-27. PubMed ID: 210352
[TBL] [Abstract][Full Text] [Related]
18. Studies of a variant very-low-density lipoprotein with an acquired deficiency of apolipoprotein C-II.
Reckless JP; Stocks J; Holdsworth G; Galton DJ; Suggett AJ; Walton KW
Clin Sci (Lond); 1982 Jan; 62(1):93-100. PubMed ID: 7056035
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
[TBL] [Abstract][Full Text] [Related]
20. Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III.
Sun HY; Lin CC; Lee JC; Wang SW; Cheng PN; Wu IC; Chang TT; Lai MD; Shieh DB; Young KC
Gut; 2013 Aug; 62(8):1193-203. PubMed ID: 22689516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
